This article considers force use in clinical settings after a triggering event—a behavioral or medical crisis—and considers how it should be implemented.
AMA J Ethics. 2021;23(4):E326-334. doi:
10.1001/amajethics.2021.326.
This third era of opioids ruining thousands of US lives follows a first era of iatrogenic addiction stemming from the Harrison Act of 1914, and a second was marked by changes in pain treatment attitudes between 1950 and 1970.
AMA J Ethics. 2020;22(8):E729-734. doi:
10.1001/amajethics.2020.729.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.